{"id":4096,"date":"2018-04-06T10:09:41","date_gmt":"2018-04-06T14:09:41","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=4096"},"modified":"2018-04-06T10:09:41","modified_gmt":"2018-04-06T14:09:41","slug":"alzheon-inc-ipo-preview-alzh","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/alzheon-inc-ipo-preview-alzh\/","title":{"rendered":"Alzheon Inc. #IPO Preview ($ALZH)"},"content":{"rendered":"<p><a href=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/04\/ALZH.jpg\"><img decoding=\"async\" class=\"aligncenter size-full wp-image-4097\" src=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/04\/ALZH.jpg\" alt=\"ALZH\" width=\"207\" height=\"86\" \/><\/a><\/p>\n<p>Company: <strong>Alzheon Inc.<\/strong><br \/>\nSymbol: ALZH<br \/>\nDescription: They are a clinical stage biopharmaceutical company with a Phase 3-ready program in Alzheimers disease and a discovery platform of small molecules for the inhibition of protein misfolding in neurodegenerative disorders.<br \/>\nTrade Date: 4\/12<br \/>\nShares: 5 million<br \/>\nPrice Range: $13.00-$15.00<br \/>\nUnderwriter(s): Citigroup, Piper Jaffray<br \/>\nCo-Manager(s): Canaccord Genuity, JMP Securities<br \/>\nTerms Added: 4-2-18<\/p>\n<p><strong><a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1582636\/000119312518103890\/d503060ds1a.htm#toc\" target=\"_blank\">Link to S-1\/A Prospectus<\/a><\/strong><\/p>\n<p><strong><a href=\"http:\/\/www.retailroadshow.com\/wp\/roadshows.asp\" target=\"_blank\">Link to Retail Roadshow<\/a><\/strong><\/p>\n<p><strong>Business<\/strong>:\u00a0Their lead product candidate,\u00a0ALZ-801,\u00a0is an orally administered inhibitor of beta amyloid misfolding. Beta amyloids are protein fragments that, when they misfold, form small neurotoxic aggregates, or oligomers. They believe that they are the only company developing a clinical stage small molecule with a mechanism of action designed to prevent the misfolding and aggregation of beta amyloid protein into neurotoxic oligomers. In their\u00a0post hoc analyses of data from 16 clinical trials conducted by Bellus Health, Inc., they observed promising clinical signals in a subset of patients with two copies of the APOE4 gene, or APOE4\/4 homozygotes, who have greater beta amyloid burden and develop AD earlier. To their knowledge, of the 87 product candidates currently in clinical development for AD, eight, including\u00a0ALZ-801,\u00a0have received Fast Track designation. Their platform includes multiple proprietary libraries of over 10 unique chemotypes representing chemical diversity of more than 5,000 compounds with the potential to inhibit protein misfolding and disrupt protein-protein interactions, and prevent pathogenic processes leading to neurodegeneration. They are developing and optimizing the next generation of protein misfolding inhibitors for neurodegenerative diseases.<\/p>\n<p><strong>Book-Building Status<\/strong>: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.<\/p>\n<p><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\"><span style=\"font-weight: 400;\">IPO Boutique subscription clients receive daily updates on this critical information.<\/span><\/a><\/p>\n<p><strong>Conclusion<\/strong>: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a\u00a0<a href=\"https:\/\/www.ipoboutique.com\/cgi\/ipo-track-record-summary-report.php\"><span style=\"font-weight: 400;\">track record<\/span><\/a>\u00a0with our performance for last 12 years at our website. Additionally, here&#8217;s a<a href=\"http:\/\/www.ipoboutique.com\/blog\/?p=3655\"> 2017 recap of our performance<\/a>\u00a0to showcase the value of IPO Boutique&#8217;s service.<\/p>\n<p><b>Indicate with confidence,\u00a0<\/b><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\"><b>SUBSCRIBE<\/b><\/a><b>\u00a0today.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company: Alzheon Inc. Symbol: ALZH Description: They are a clinical stage biopharmaceutical company with a Phase 3-ready program in Alzheimers disease and a discovery platform of small molecules for the inhibition of protein misfolding in neurodegenerative disorders. Trade Date: 4\/12 Shares: 5 million Price Range: $13.00-$15.00 Underwriter(s): Citigroup, Piper Jaffray Co-Manager(s): Canaccord Genuity, JMP Securities[&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[1],"tags":[],"class_list":["post-4096","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=4096"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4096\/revisions"}],"predecessor-version":[{"id":4098,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4096\/revisions\/4098"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=4096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=4096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=4096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}